Is CA125 useful in monitoring patients with platinum resistant ovarian cancer? Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, July 11, 2016

Is CA125 useful in monitoring patients with platinum resistant ovarian cancer?



open access (pdf)


References:
1. Eisenhauer EA, Therasse P, Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009 Jan;45(2):228-47
2. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J ClinOncol 2003;21: 187s-193s.
3. Rustin GJ, Vergote I, Eisenhauer E et al. Definitions for response and progression in ovarian cancerclinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).Int J Gynecol Cancer 2011; 21: 419-423.
4. K Lindemann, G Kristensen, M Raza Mirza, et al Poor concordance between CA-125 and RECIST at the time of disease progression inpatients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial. Annals oncol in press.

0 comments :

Post a Comment

Your comments?